Everett Vokes to Celecoxib
This is a "connection" page, showing publications Everett Vokes has written about Celecoxib.
Connection Strength
0.122
-
Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting. Lung Cancer. 2003 Aug; 41 Suppl 1:S115-21.
Score: 0.050
-
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol. 2017 Jul 01; 35(19):2184-2192.
Score: 0.033
-
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. J Thorac Oncol. 2011 Nov; 6(11):1902-6.
Score: 0.022
-
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 2008 Feb 20; 26(6):848-55.
Score: 0.017